CYCLOPHOSPHAMIDE for Focal segmental glomerulosclerosis: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

There are 49 adverse event reports in the FDA FAERS database where CYCLOPHOSPHAMIDE was used for Focal segmental glomerulosclerosis.

Most Reported Side Effects for CYCLOPHOSPHAMIDE

Side Effect	Reports	%	Deaths	Hosp.
Off label use	12,578	9.8%	2,788	3,928
Febrile neutropenia	11,318	8.8%	1,348	7,223
Drug ineffective	8,142	6.3%	2,157	2,184
Neutropenia	7,352	5.7%	1,287	2,890
Disease progression	7,100	5.5%	1,730	1,008
Pyrexia	6,126	4.8%	832	4,228
Product use in unapproved indication	5,750	4.5%	1,245	1,392
Thrombocytopenia	4,669	3.6%	902	1,799
Pneumonia	4,595	3.6%	1,633	2,604
Nausea	4,561	3.6%	363	2,190
Anaemia	4,486	3.5%	664	2,040
Death	4,270	3.3%	4,260	453
Sepsis	4,041	3.1%	2,077	1,841
Myelosuppression	3,603	2.8%	209	1,796
Diarrhoea	3,602	2.8%	566	1,861